Teva Pharmaceutical Industries (TEVA) Competitors

GSK (NYSE:GSK) and Teva Pharmaceutical Industries (NYSE:TEVA) are both large-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, dividends, institutional ownership, media sentiment, risk, profitability, analyst recommendations, valuation and community ranking.

Which has stronger earnings and valuation, GSK or TEVA?

GSK has higher revenue and earnings than Teva Pharmaceutical Industries. Teva Pharmaceutical Industries is trading at a lower price-to-earnings ratio than GSK, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GSK	$37.71B	1.83	$6.13B	$1.54	21.67
Teva Pharmaceutical Industries	$15.85B	1.56	-$559M	-$0.85	-25.65

Does the MarketBeat Community prefer GSK or TEVA?

Teva Pharmaceutical Industries received 508 more outperform votes than GSK when rated by MarketBeat users. Likewise, 67.82% of users gave Teva Pharmaceutical Industries an outperform vote while only 57.10% of users gave GSK an outperform vote.

Company	Underperform	Outperform
GSK	Outperform Votes 820 57.10%	Underperform Votes 616 42.90%
Teva Pharmaceutical Industries	Outperform Votes 1328 67.82%	Underperform Votes 630 32.18%

Does the media favor GSK or TEVA?

In the previous week, GSK had 5 more articles in the media than Teva Pharmaceutical Industries. MarketBeat recorded 19 mentions for GSK and 14 mentions for Teva Pharmaceutical Industries. Teva Pharmaceutical Industries' average media sentiment score of 0.64 beat GSK's score of 0.47 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GSK	8 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Teva Pharmaceutical Industries	7 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more volatility and risk, GSK or TEVA?

GSK has a beta of 0.63, suggesting that its share price is 37% less volatile than the S&P 500. Comparatively, Teva Pharmaceutical Industries has a beta of 0.73, suggesting that its share price is 27% less volatile than the S&P 500.

Do insiders & institutionals have more ownership in GSK or TEVA?

15.7% of GSK shares are held by institutional investors. Comparatively, 54.1% of Teva Pharmaceutical Industries shares are held by institutional investors. 10.0% of GSK shares are held by company insiders. Comparatively, 0.6% of Teva Pharmaceutical Industries shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Is GSK or TEVA more profitable?

GSK has a net margin of 7.97% compared to Teva Pharmaceutical Industries' net margin of -5.73%. GSK's return on equity of 50.62% beat Teva Pharmaceutical Industries' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GSK	7.97%	50.62%	11.54%
Teva Pharmaceutical Industries	-5.73%	42.92%	7.25%

Do analysts rate GSK or TEVA?

GSK currently has a consensus price target of $43.25, indicating a potential upside of 29.59%. Teva Pharmaceutical Industries has a consensus price target of $22.13, indicating a potential upside of 1.47%. Given GSK's higher possible upside, analysts clearly believe GSK is more favorable than Teva Pharmaceutical Industries.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GSK	0 Sell rating(s)	7 Hold rating(s)	0 Buy rating(s)	3 Strong Buy rating(s)	2.60
Teva Pharmaceutical Industries	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.75

Summary

GSK beats Teva Pharmaceutical Industries on 12 of the 19 factors compared between the two stocks.